Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Metastasis ; 41(3): 219-228, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38416302

RESUMO

High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells. A stable liquid biopsy biomarker for non-small cell lung cancer lung cancer has yet to be approved for clinical use. We performed a cross-sectional single-site study, and collected liquid biopsies from patients diagnosed with early, locally advanced, or metastatic lung cancer, undergoing surgery, or systemic therapy (chemotherapy/checkpoint inhibitors). Evaluation of overall circulating tumour cell counts, or cluster counts did not correlate with patient outcome. Interestingly, the numbers of Pan cytokeratin positive circulating tumour cells engulfed by tumour associated monocytes correlated strongly with patient outcome independent of circulating tumour cell counts and the use of checkpoint inhibitors. We suggest that Pan cytokeratin staining within monocytes is an important indicator of tumour-associated inflammation post-therapy and an effective biomarker with strong prognostic capability for patient outcome.


Assuntos
Carcinoma Pulmonar de Células não Pequenas , Queratinas , Neoplasias Pulmonares , Monócitos , Células Neoplásicas Circulantes , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/metabolismo , Células Neoplásicas Circulantes/patologia , Células Neoplásicas Circulantes/metabolismo , Masculino , Feminino , Queratinas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Monócitos/metabolismo , Idoso , Pessoa de Meia-Idade , Estudos Transversais , Biomarcadores Tumorais/metabolismo , Prognóstico , Biópsia Líquida/métodos , Inibidores de Checkpoint Imunológico/uso terapêutico , Idoso de 80 Anos ou mais , Adulto
2.
Front Immunol ; 13: 871217, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35514990

RESUMO

A man in his early 50s presented with small bowel obstruction, requiring emergency laparoscopic small bowel resection for the metastatic melanoma of the jejunum with no identifiable primary lesion. One week after his first treatment with ipilimumab and nivolumab, he presented with diffuse abdominal pain, constipation, and fatigue. A computerized tomography scan did not identify a cause for his symptoms. This was rapidly followed by thrombocytopenia on day 11 and then anemia. He commenced intravenous corticosteroids for a suspected diagnosis of immune-related thrombocytopenia. On day 15, a generalized onset motor seizure occurred, and despite plasmapheresis later that day, the patient died from fatal immune-related thrombotic thrombocytopenic purpura (TTP). This was confirmed with suppressed ADAMTS13 (<5%) testing on day 14. Immune-related TTP is a rare and, in this case, fatal immune- related adverse event. Further studies are required to identify additional immunosuppressive management for immune-related TTP.


Assuntos
Melanoma , Segunda Neoplasia Primária , Púrpura Trombocitopênica Idiopática , Púrpura Trombocitopênica Trombótica , Humanos , Fatores Imunológicos , Imunoterapia , Ipilimumab/efeitos adversos , Masculino , Melanoma/tratamento farmacológico , Nivolumabe/efeitos adversos , Púrpura Trombocitopênica Trombótica/diagnóstico
5.
Ir J Med Sci ; 186(3): 571-575, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28039597

RESUMO

BACKGROUND: Breast carcinoma metastasis to the gastrointestinal tract is rare and more frequently associated with lobular than ductal carcinoma (Borst and Ingold, Surg 114(4):637-641 [1]). The purpose of this article is to present a case based review of a unique gastrointestinal metastasis and literature review. METHODS: A 46 year old lady with metastatic invasive ductal breast cancer was admitted to A&E with sudden onset of epigastric and left shoulder pain. She completed the first cycle of capecitabine/vinorelbine 1 week previously. Clinical examination revealed a tender epigastrium with rigidity in the upper abdomen. Free air under the diaphragm and a positive Rigler's sign was radiologically identified. A laparoscopy demonstrated a fibrinous exudate in the left upper quadrant consistent with a walled off lesser curvature gastric perforation. A subsequent oesophagogastroduodenoscopy (OGD) demonstrated a healed gastric ulcer of benign appearance; however the pathology confirmed metastatic breast carcinoma. RESULTS: Literature review confirmed no previously reported cases of vinorelbine induced gastric perforation. Four cases of metastatic breast cancer with gastric metastasis presenting with perforation were identified; three of these cases (Fra et al., Presse Med 25(26):1215 (1996) [2], Solis-Caxaj et al., Gastroenterol Clin Biol 28(1):91-92 (2004) [3], Ghosn et al., Bull Cancer 78(11):1071-1073 (1991) [4]), were in the French medical literature, including one male patient (Fra et al., Presse Med 25(26):1215 (1996) [2]) and at least one ductal breast carcinoma (Solis-Caxaj et al., Gastroenterol Clin Biol 28(1):91-92 (2004) [3]). The fourth case (van Geel et al., Ned Tijdschr Geneeskd 144(37):1761-1763 (2000) [5]), was in the Dutch medical literature and a lobular breast carcinoma. CONCLUSION: This case represents a rare complication of breast cancer chemotherapy, the subsequent significant benefit the patient received from treatment is consistent with the chemosensitivity to therapy that also resulted in gastric perforation. Five years after gastric perforation she resumed palliative chemotherapy after progression on sequential hormonal therapies.


Assuntos
Antineoplásicos Fitogênicos/efeitos adversos , Neoplasias da Mama/complicações , Neoplasias Gástricas/induzido quimicamente , Vimblastina/análogos & derivados , Adulto , Antineoplásicos Fitogênicos/farmacologia , Neoplasias da Mama/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Gástricas/patologia , Neoplasias Gástricas/secundário , Vimblastina/efeitos adversos , Vimblastina/farmacologia , Vinorelbina
6.
N J Med ; 86(7): 541-4, 1989 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-2755614

RESUMO

An acute confusional state after infarction in the distribution of the right middle cerebral artery has been described. Patient recovery usually is excellent. Some patients, however, do not improve, resulting in a chronic confusional state.


Assuntos
Transtornos Cerebrovasculares/complicações , Transtornos Cognitivos/etiologia , Confusão/etiologia , Idoso , Angiografia Cerebral , Transtornos Cerebrovasculares/diagnóstico por imagem , Doença Crônica , Humanos , Masculino
8.
Neurology ; 32(8): 912-3, 1982 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7201590

RESUMO

Four patients with disabling action tremor in the setting of MS were treated with isoniazid (800 to 1200 mg per day). All patients showed significant improvement of the tremor, allowing more functional use of their extremities. To the best of our knowledge, this is the only medical treatment for this type of tremor.


Assuntos
Isoniazida/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Tremor/tratamento farmacológico , Adulto , Animais , Química Encefálica/efeitos dos fármacos , Eletromiografia , Feminino , Humanos , Masculino , Tremor/fisiopatologia , Ácido gama-Aminobutírico/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...